India Global Trial Hub Dreams Still Distant As Concerns Linger
Executive Summary
Indian clinical trial approvals appear to be on the downswing despite government moves to boost the troubled sector, as regulatory uncertainty and negative publicity continue to undermine confidence in the industry.
You may also be interested in...
India’s Micro Therapeutic says EMA’s ‘Sweep’ Suspension Will Hurt; CRO Industry Shuns ‘Bad Eggs’
Data integrity concerns continue to cloud outlook for India’s contract research sector. The European Medicines Agency’s latest action against Micro Therapeutic Research Labs suspends more than 300 products in the EU over “unreliable” data and the firm tells Pink Sheet this will result in a “considerable dent” in its operations.
Another Indian CRO Under EMA Lens Over Dirty Data Concerns
Micro Therapeutic Research Labs is now under the scanner over alleged data integrity concerns. European Medicines Agency (EMA) is evaluating medicines based on studies done by the Indian firm.
Indian Clinical Research Sector: Hope And Despair Amid Shutdowns
India's clinical research segment has had a rough time of late. Uncertainties, evolving regulations and compliance deviations have hurt the sector that is now scarred with firms downing the shutter, mistrust and constant speculation. Scrip spoke to a number of CROs who appear to have weathered the storm, but it seems the industry may not be out of the woods just yet.